Nuvation Bio Inc. — Form 10-Q
Filed November 4, 2026 · analyzed by the Periodic Agent
10-Q
— Neutral
significance 28/100
What the filing says
Nuvation amended its October 2023 license agreement with Nippon Kayaku (NK) to establish joint sponsorship of the AB-106-G319 Phase 3 trial for taletrectinib in ROS1-fusion positive lung cancer; Nuvation sponsors and manages the trial while NK bears [redacted] of out-of-pocket costs in the territory, with Nuvation retaining publication authority. Separately, Nuvation amended its April 2026 Daiichi Sankyo license agreement to finalize Exhibit H regarding safusidenib data (contents redacted as confidential).
Why this rating
Routine amendments clarifying trial sponsorship and cost-sharing; no disclosed financial terms or equity changes. Administrative in nature relative to $497M market cap.
See more from November 4, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.